Faes Farma SA (FAE) - Total Assets
Based on the latest financial reports, Faes Farma SA (FAE) holds total assets worth €1.34 Billion EUR (≈ $1.57 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore FAE operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Faes Farma SA - Total Assets Trend (2000–2025)
This chart illustrates how Faes Farma SA's total assets have evolved over time, based on quarterly financial data. See Faes Farma SA (FAE) net assets for net asset value and shareholders' equity analysis.
Faes Farma SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Faes Farma SA's total assets of €1.34 Billion consist of 36.0% current assets and 64.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.7% |
| Accounts Receivable | €167.30 Million | 12.5% |
| Inventory | €185.01 Million | 13.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €199.40 Million | 14.9% |
| Goodwill | €258.48 Million | 19.3% |
Asset Composition Trend (2000–2025)
This chart illustrates how Faes Farma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Faes Farma SA market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Faes Farma SA's current assets represent 36.0% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, up from 2.5% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 26.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 19.3% of total assets.
Faes Farma SA Competitors by Total Assets
Key competitors of Faes Farma SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
Faes Farma SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.61 | 3.23 | 3.42 |
| Quick Ratio | 1.61 | 1.85 | 2.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €297.52 Million | €230.27 Million | €205.32 Million |
Faes Farma SA - Advanced Valuation Insights
This section examines the relationship between Faes Farma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.04 |
| Latest Market Cap to Assets Ratio | 1.12 |
| Asset Growth Rate (YoY) | 57.3% |
| Total Assets | €1.34 Billion |
| Market Capitalization | $1.50 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Faes Farma SA's assets above their book value (1.12x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Faes Farma SA's assets grew by 57.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Faes Farma SA (2000–2025)
The table below shows the annual total assets of Faes Farma SA from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.34 Billion ≈ $1.57 Billion |
+57.30% |
| 2024-12-31 | €853.08 Million ≈ $997.34 Million |
+9.93% |
| 2023-12-31 | €776.03 Million ≈ $907.26 Million |
+6.94% |
| 2022-12-31 | €725.67 Million ≈ $848.38 Million |
+13.07% |
| 2021-12-31 | €641.76 Million ≈ $750.29 Million |
+13.76% |
| 2020-12-31 | €564.15 Million ≈ $659.55 Million |
+14.28% |
| 2019-12-31 | €493.67 Million ≈ $577.16 Million |
+2.68% |
| 2018-12-31 | €480.80 Million ≈ $562.11 Million |
+11.75% |
| 2017-12-31 | €430.24 Million ≈ $503.00 Million |
+29.89% |
| 2016-12-31 | €331.22 Million ≈ $387.23 Million |
+13.95% |
| 2015-12-31 | €290.68 Million ≈ $339.83 Million |
+8.77% |
| 2014-12-31 | €267.23 Million ≈ $312.42 Million |
-6.29% |
| 2013-12-31 | €285.16 Million ≈ $333.38 Million |
-0.59% |
| 2012-12-31 | €286.84 Million ≈ $335.35 Million |
-1.47% |
| 2011-12-31 | €291.12 Million ≈ $340.35 Million |
-2.01% |
| 2010-12-31 | €297.10 Million ≈ $347.34 Million |
+25.91% |
| 2009-12-31 | €235.97 Million ≈ $275.87 Million |
-14.20% |
| 2008-12-31 | €275.01 Million ≈ $321.52 Million |
+0.95% |
| 2007-12-31 | €272.43 Million ≈ $318.50 Million |
+17.21% |
| 2006-12-31 | €232.43 Million ≈ $271.74 Million |
+7.59% |
| 2005-12-31 | €216.04 Million ≈ $252.58 Million |
+8.41% |
| 2004-12-31 | €199.29 Million ≈ $232.99 Million |
+0.64% |
| 2003-12-31 | €198.01 Million ≈ $231.49 Million |
+11.93% |
| 2002-12-31 | €176.91 Million ≈ $206.83 Million |
-99.28% |
| 2001-12-31 | €24.57 Billion ≈ $28.73 Billion |
+1.51% |
| 2000-12-31 | €24.21 Billion ≈ $28.30 Billion |
-- |
About Faes Farma SA
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants servic… Read more